Parker Institute summoned the neoantigen pioneers to compare their prediction algorithms. And they have some suggestions for the field

What makes a good neoantigen?

For all the promises of the bold new approach to cancer vaccines and therapies — zeroing in on specific mutated antigens expressed only by tumors — companies and academics have little way of knowing how good they are at predicting which neoantigens represent the best targets. There’s no standard or baseline for players to stack themselves against rivals in the nascent field, and by the time they find out, it could be too late.

No single group could really build that benchmark. Precious proprietary information is at stake, not to mention tremendous resources required.